About Clovis Oncology (NASDAQ:CLVS)
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company's product candidates include lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors; and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor. It distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; collaboration and license agreement with Les Laboratoires Servier; a clinical collaboration with Bristol-Myers Squibb Company; a partnership with Foundation Medicine, Inc; and a diagnostic collaboration with Myriad Genetics, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CLVS
CUSIP18946410
Phone303-625-5000
Debt
Debt-to-Equity Ratio0.77%
Current Ratio7.69%
Quick Ratio7.35%
Price-To-Earnings
Trailing P/E Ratio-10.02
Forward P/E Ratio-10.67
P/E GrowthN/A
Sales & Book Value
Annual Sales$55.51 million
Price / Sales48.44
Cash FlowN/A
Price / CashN/A
Book Value$7.50 per share
Price / Book6.84
Profitability
EPS (Most Recent Fiscal Year)($5.12)
Net Income$-346,390,000.00
Net Margins-624.02%
Return on Equity-81.34%
Return on Assets-32.92%
Miscellaneous
Employees360
Outstanding Shares52,400,000
Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions
What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
How were Clovis Oncology's earnings last quarter?
Clovis Oncology (NASDAQ:CLVS) posted its quarterly earnings results on Monday, February, 26th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.25. The biopharmaceutical company had revenue of $17.04 million for the quarter, compared to the consensus estimate of $19.42 million. Clovis Oncology had a negative return on equity of 81.34% and a negative net margin of 624.02%. The firm's quarterly revenue was up 21746.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.83) EPS. View Clovis Oncology's Earnings History.
When is Clovis Oncology's next earnings date?
What price target have analysts set for CLVS?
16 brokerages have issued 1-year price objectives for Clovis Oncology's shares. Their forecasts range from $50.00 to $125.00. On average, they anticipate Clovis Oncology's share price to reach $87.04 in the next twelve months. View Analyst Ratings for Clovis Oncology.
What are Wall Street analysts saying about Clovis Oncology stock?
Here are some recent quotes from research analysts about Clovis Oncology stock:
- 1. According to Zacks Investment Research, "Clovis’ Rubraca has not performed well in 2017 as it registered slower-than-expected sales. Nonetheless, Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Clovis is focused on continued approval for the drug. Rubraca is under review in EU for the same indication. A potential approval in Europe and in second-line setting in the United States will give a boost for the company. Several studies evaluating Rubraca in different types of ovarian cancer patients are ongoing. Clovis is looking for label expansion in second line or later maintenance treatment for advanced ovarian cancer. However, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Clovis’ shares have underperformed the industry in the past six months. Loss estimates have widened ahead of Q1 results. Clovis has a mixed record of earnings surprises in the recent quarters." (4/19/2018)
- 2. Cann analysts commented, "The approval of the sNDA is in line with our expectations and supports our anticipated launch in this setting in Q2 2018. We estimate the impact of this approval will account for 56.7% of 2018 sales and will increase to 70.4% of sales in 2022. Therefore, our outlook remains unchanged." (4/8/2018)
- 3. JPMorgan Chase analysts commented, "2018 Procedure Growth Guidance Should Help Shares ISRG reported preliminary 4Q17 revenue of $892M (18% y/y), above our forecast of $865M and consensus’ estimates of $847M. Procedure growth of 17% came in higher than our 16.2% estimate and the Street’s 15.1% forecast. The sales breakout for 4Q included $457 in instrument revenue, $283 in system sales, and $153 for service, higher than our and Street estimates in each segment. 2018 guidance calls for 11-15% procedure growth, above our 10.9% forecast and in-line with consensus growth of 12.8%. This beat on revenue and procedure growth matched our expectations going into the report. Stellar revenue, strong procedure growth, and in-line 2018 guidance should boost shares today. There were 216 systems shipped in the quarter, well above our 180 unit estimate and the Street’s 187. Of these, 40 were shipped under operating lease agreements. However, implied system ASPs were $1.31M, below our modeled $1.55M and a more than $200Ksequential decline from Q3." (1/11/2018)
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include Ionis Pharmaceuticals (IONS), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Gal�pagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), Blueprint Medicines (BPMC), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND), Advanced Accelerator Application (AAAP), Array Biopharma (ARRY), Tesaro (TSRO), Amicus Therapeutics (FOLD) and Ascendis Pharma (ASND).
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the folowing people:
- Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
- Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
- Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
- Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
- Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)
Has Clovis Oncology been receiving favorable news coverage?
News stories about CLVS stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Clovis Oncology earned a news impact score of 0.12 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 47.74 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Clovis Oncology?
Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clovis Oncology's stock price today?
One share of CLVS stock can currently be purchased for approximately $51.32.
How big of a company is Clovis Oncology?
Clovis Oncology has a market capitalization of $2.79 billion and generates $55.51 million in revenue each year. The biopharmaceutical company earns $-346,390,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Clovis Oncology employs 360 workers across the globe.
How can I contact Clovis Oncology?
Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]
MarketBeat Community Rating for Clovis Oncology (CLVS)
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Clovis Oncology (NASDAQ:CLVS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
16 Wall Street analysts have issued ratings and price targets for Clovis Oncology in the last 12 months. Their average twelve-month price target is $87.04, suggesting that the stock has a possible upside of 69.60%. The high price target for CLVS is $125.00 and the low price target for CLVS is $50.00. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.76 | 2.65 | 2.59 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $87.04 | $87.3571 | $90.3077 | $85.7857 |
| Price Target Upside: | 69.60% upside | 57.37% upside | 64.41% upside | 2.74% upside |
Clovis Oncology (NASDAQ:CLVS) Consensus Price Target History
Clovis Oncology (NASDAQ:CLVS) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Clovis Oncology (NASDAQ:CLVS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Clovis Oncology (NASDAQ CLVS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 12.50%
Clovis Oncology (NASDAQ CLVS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/9/2018 | Thorlef Spickschen | Director | Sell | 4,500 | $60.02 | $270,090.00 | 7,618 |  |
| 3/8/2018 | Thorlef Spickschen | Director | Sell | 4,500 | $61.47 | $276,615.00 | 12,118 | |
| 2/22/2018 | Thorlef Spickschen | Director | Sell | 4,500 | $60.00 | $270,000.00 | 16,618 | |
| 2/15/2018 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $54.09 | $162,270.00 | 180,571 | |
| 1/16/2018 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $59.16 | $177,480.00 | 183,571 | |
| 1/8/2018 | Thorlef Spickschen | Director | Sell | 4,500 | $64.97 | $292,365.00 | 21,118 | |
| 12/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $64.16 | $192,480.00 | 182,583 | |
| 12/8/2017 | Thorlef Spickschen | Director | Sell | 4,500 | $60.00 | $270,000.00 | 25,618 | |
| 11/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $63.70 | $191,100.00 | | |
| 10/16/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $84.54 | $253,620.00 | | |
| 9/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $69.50 | $208,500.00 | 191,583 | |
| 8/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $70.05 | $210,150.00 | 194,583 | |
| 8/4/2017 | James C Blair | Director | Sell | 18,450 | $78.61 | $1,450,354.50 | 2,185 | |
| 7/17/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $91.56 | $274,680.00 | 197,583 | |
| 6/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $61.82 | $185,460.00 | 200,583 | |
| 5/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $47.39 | $142,170.00 | 203,583 | |
| 4/17/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $56.02 | $168,060.00 | 206,583 | |
| 3/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $66.99 | $200,970.00 | 209,583 | |
| 11/2/2015 | Erle T. Mast | CFO | Sell | 3,000 | $105.56 | $316,680.00 | 135,583 | |
| 10/28/2015 | Lindsey Rolfe | insider | Sell | 4,000 | $98.02 | $392,080.00 | | |
| 10/15/2015 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $91.91 | $275,730.00 | 212,583 | |
| 10/5/2015 | Lindsey Rolfe | insider | Sell | 4,000 | $93.04 | $372,160.00 | | |
| 10/1/2015 | Erle T. Mast | CFO | Sell | 3,000 | $90.22 | $270,660.00 | 138,583 | |
| 9/18/2015 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $112.56 | $337,680.00 | 215,583 | |
| 9/1/2015 | Erle T. Mast | CFO | Sell | 3,000 | $79.51 | $238,530.00 | 141,583 | |
| 7/1/2015 | Erle T Mast | CFO | Sell | 3,000 | $85.70 | $257,100.00 | | |
| 6/1/2015 | Erle T Mast | CFO | Sell | 3,000 | $88.78 | $266,340.00 | | |
| 5/15/2015 | M James Barrett | Director | Sell | 2,424 | $92.43 | $224,050.32 | | |
| 4/1/2015 | Erle T Mast | CFO | Sell | 3,000 | $71.25 | $213,750.00 | | |
| 3/9/2015 | Erle T Mast | CFO | Sell | 9,000 | $78.84 | $709,560.00 | | |
| 3/5/2015 | James C Blair | Director | Sell | 8,528 | $77.70 | $662,625.60 | | |
| 1/16/2015 | Steven L Hoerter | Insider | Sell | 10,000 | $67.00 | $670,000.00 | | |
| 12/11/2013 | Erle Mast | CFO | Sell | 50,000 | $52.78 | $2,639,000.00 | 168,583 | |
| 12/5/2013 | Thorlef Spickschen | Director | Sell | 9,000 | $56.10 | $504,900.00 | 34,427 | |
| 6/5/2013 | Andrew R Allen | Insider | Sell | 22,594 | $68.54 | $1,548,592.76 | | |
| 6/4/2013 | M James Barrett | Director | Sell | 2,483 | $70.80 | $175,796.40 | | |
| 6/4/2013 | Parters Vii L P Domain | Major Shareholder | Sell | 159,192 | $64.58 | $10,280,619.36 | | |
| 6/4/2013 | Steven L Hoerter | Insider | Sell | 10,000 | $73.06 | $730,600.00 | | |
| 3/6/2013 | Parters Vii L P Domain | Major Shareholder | Sell | 250,000 | $24.59 | $6,147,500.00 | | |
| 8/16/2012 | Edward J Mckinley | Director | Buy | 9,701 | $15.50 | $150,365.50 | | |
(Data available from 1/1/2013 forward)
Clovis Oncology (NASDAQ CLVS) News Headlines
| Source: |
|
Clovis Oncology (NASDAQ:CLVS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Clovis Oncology (NASDAQ:CLVS) Income Statement, Balance Sheet and Cash Flow Statement
Clovis Oncology (NASDAQ CLVS) Stock Chart for Friday, April, 20, 2018
Loading chart…
